Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results From the Global Burden of Disease Study 2019
Overview
Affiliations
Non-Hodgkin lymphoma is a common hematologic malignancy. This article aimed to estimate the trends of non-Hodgkin lymphoma (NHL) globally from 1990 to 2019. Data on the NHL burden were explored from the Global Burden of Disease study 2019. The trends of NHL burden were estimated using age-standardized rate (ASR) and estimated annual percentage change (EAPC). The ASR of NHL incidence showed an increasing trend worldwide from 1990 to 2019, with an EAPC of.56 [95% CI: 0.45-0.66]. Meanwhile, increasing trends were observed in both sexes and in most geographic regions, particularly East Asia (EAPC = 3.57, 95% CI: 3.29-3.86). The most pronounced increasing trends were seen in Georgia (EAPC = 4.7, 95% CI: 4.20-5.21), followed by Belarus and Uzbekistan. However, death and disability-adjusted life years (DALYs) caused by NHL showed decreasing trends globally, in which the respective EAPCs were -0.09 (95% CI: -0.17 to -0.02) and -0.28 (95% CI: -0.35 to -0.22). Decreasing trends were mainly seen in high and high-middle sociodemographic index (SDI) areas. At the national level, the largest increasing trends of death and DALYs were observed in Georgia, in which the respective EAPCs were 4.54 (95% CI: 4.01-5.07) and 4.97 (95% CI: 4.42-5.52). Decreasing trends of death and DALYs caused by NHL were observed worldwide from 1990 to 2019, but NHL remains a substantial challenge globally. The findings would inform the strategies for reducing the burden of NHL.
Harahap A, Ham M, Kurniawan A, Charles S, Wijovi F, Sukrisman L JCO Glob Oncol. 2024; 10:e2400346.
PMID: 39509674 PMC: 11583351. DOI: 10.1200/GO-24-00346.
Song N, Musa H, Soriano M, Hibbs D, Ramzan I, Ong J Ann Hematol. 2024; 103(11):4607-4612.
PMID: 39249493 PMC: 11534887. DOI: 10.1007/s00277-024-05981-9.
Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies.
Luo J, Craver A, Bahl K, Stepniak L, Moore K, King J J Natl Cancer Cent. 2024; 2(4):226-234.
PMID: 39036553 PMC: 11256700. DOI: 10.1016/j.jncc.2022.08.003.
Liu J Dialogues Health. 2024; 4:100182.
PMID: 38846580 PMC: 11153881. DOI: 10.1016/j.dialog.2024.100182.
Daneels W, Van Parys A, Huyghe L, Rogge E, De Rouck S, Christiaen R Exp Hematol Oncol. 2024; 13(1):59.
PMID: 38831452 PMC: 11145843. DOI: 10.1186/s40164-024-00524-4.